http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2554646-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6c82f1477b71e93f1ff6e9b27d67ec77 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D207-48 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D207-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D207-09 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D207-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D207-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D207-09 |
| filingDate | 2008-02-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_688a907b01c964f803e65ccd050680ca http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7d82a41ca9805d57fd625ad4ed7f2478 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6a4f52b0861beba2cdb4ef33d298f5db http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c9af2c29070bebf24a11474cb3bc3bd2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e039b717aada065abf9110a872e4294a |
| publicationDate | 2015-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2554646-T3 |
| titleOfInvention | Quaternary ammonium diphenylmethyl compounds, useful as muscarinic receptor antagonists |
| abstract | A compound of the formula I: ** Formula ** in the form of a salt, or of a hybrid ion (zwitterion), wherein: a and b are, independently, 0 or an integer from 1 to 5; each R1 and R2 are independently selected from -C1-4alkyl, -C2-4alkenyl, -C2-4alkynyl, - C3-6cycloalkyl, cyano, halo, -ORa, -CH2OH, - COOH, - C (O) O-C1-4 alkyl, -C (O) NRbRc, -SRa, -S (O) Ra, -S (O) 2Ra, and -NRbRc; wherein each Ra is independently selected from hydrogen, C1-4alkyl, -C2-4alkenyl, -C2-4alkynyl and -C3-6cycloalkyl; each Rb and Rc is independently selected from hydrogen, -C1-4alkyl, -C2-4alkenyl, -C2-4alkynyl or -C3-6 cycloalkyl; or Rb and Rc, together with the nitrogen atom to which they are attached, form a C3-6 heterocycle, or two contiguous R1 groups, or two contiguous R2 groups, are joined together to form a - alkylene, - alkylene C2-4-O- or -O-alkylene C1-- 4-O-; R3 represents -C (O) NR3aR3b; R3a and R3b are independently selected from hydrogen, -C1-6alkyl, -C2-6alkenyl, -C2-6alkynyl, - C3-6cycloalkyl, - C6-10 aryl, - C2-heteroaryl 9, - C3-6heterocycle, and - (CH2) 1-2-R3c, where R3 is selected from -OH, -O-C1-6alkyl, - C3-6cycloalkyl, - C6-10 aryl, - heteroaryl C2-9, and - C3-6 heterocycle, or R3a and R3b, together with the nitrogen atom to which they are attached, form a C3-6 heterocycle, which optionally contains an additional, selected heteroatom between nitrogen, oxygen or sulfur; c, is 0, or an integer from 1 to 3; each R4 is independently fluoro or C1-4alkyl; d, is 1 or 2, and signifies an optional double bond; R5 is selected from -C1-6alkyl, -CH2-C2-6alkenyl, -CH2-C2-6alkynyl, and -CH2COR5a; where R5a is selected from -OH, -O-C1-6alkyl, and -NR5bR5c; and R5b and R5c, is independently selected from H and -C1-6alkyl; Q is -C0-5-alkylene-Q'- C0-1-alkylene, where Q 'is selected from -CH2-, -CH> = CH-, -C≡C-, -O-, -S- , -S (O) -, -SO2-, -SO2-NRQ1-, -NRQ1-SO2-, -C (O) -, -OC (O) -, -C (O) O-, -NRQ1C (O ) -, -C (O) NRQ1-, -NRQ2-C (O) -NRQ3-, -NRQ2-C (S) - NRQ3-, -C> = NO-, -SS-, and -C (> = NO-RQ4) -, where RQ1 is hydrogen or - C1-4alkyl, RQ2 and RQ3, are independently selected from hydrogen, - C1-4alkyl, and - C3-6cycloalkyl, or RQ2 and RQ3, are taken together, to form -C2-4alkylene, or -C2-3alkenylene, and RQ4, -C1-4alkyl or benzyl; e, is 0, or an integer from 1 to 5; each R6 is independently selected from halo, -C1-4alkyl, -C0-4alkylene-OH, cyano, -C0-2alkylene-COOH, -C (O) O-C1-4alkyl , -O-C1-4alkyl, - S-C1-4alkyl, - NH-C (O) -C1-4alkyl, -N (C1-4alkyl) 2, and -N + (O) O; wherein each alkyl, alkenyl, alkylene, alkynyl, and cycloalkyl group, at R1-3, R3a-3c, R4-6 4-6, and RaRc, is optionally substituted with 1 to 5 fluorine atoms; wherein each alkyl, alkenyl, and alkynyl group, in R5, is optionally substituted with 1 to 2 substituents, independently selected from -O-C 1-6 alkyl, -OH and phenyl; each cycloalkyl, aryl, heteroaryl and heterocycle group, in R1-2, R3a-3c, and Ra-c, is optionally substituted with 1 to 3 substituents, independently selected from -C1-4alkyl, - C2-4 alkenyl, -C2-4alkynyl, cyano, halo, -O- C1-4alkyl, -S-C1-4alkyl, -S (O) (C1-4alkyl), -S (O) 2 ( C1-4alkyl), -NH2, -NH (C1-4alkyl) and -N (C1-4alkyl) 2, where each alkyl, alkenyl and alkynyl group is optionally substituted with 1 to 5 fluoro substituents ; and each CH2- group in Q, is optionally substituted with 1 or 2 substituents, which are independently selected from -C1-2alkyl, -OH and fluoro; and if said compound is in the form of a salt, the compound in question also comprises, also, an anion, of a pharmaceutically acceptable acid. |
| priorityDate | 2007-02-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 634.